Effective reorganization and self-indexing of big semantic data

En esta tesis hemos analizado la redundancia estructural que los grafos RDF poseen y propuesto una técnica de preprocesamiento: RDF-Tr, que agrupa, reorganiza y recodifica los triples, tratando dos fuentes de redundancia estructural subyacentes a la naturaleza del esquema RDF. Hemos integrado RDF-Tr en HDT y k2-triples, reduciendo el tamaño que obtienen los compresores originales, superando a las técnicas más prominentes del estado del arte. Hemos denominado HDT++ y k2-triples++ al resultado de aplicar RDF-Tr en cada compresor. En el ámbito de la compresión RDF se utilizan estructuras compactas para construir autoíndices RDF, que proporcionan acceso eficiente a los datos sin descomprimirlos. HDT-FoQ es utilizado para publicar y consumir grandes colecciones de datos RDF. Hemos extendido HDT++, llamándolo iHDT++, para resolver patrones SPARQL, consumiendo menos memoria que HDT-FoQ, a la vez que acelera la resolución de la mayoría de las consultas, mejorando la relación espacio-tiempo del resto de autoíndices.Departamento de Informática (Arquitectura y Tecnología de Computadores, Ciencias de la Computación e Inteligencia Artificial, Lenguajes y Sistemas Informáticos)Doctorado en Informátic

RDF-TR: Exploiting structural redundancies to boost RDF compression

The number and volume of semantic data have grown impressively over the last decade, promoting compression as an essential tool for RDF preservation, sharing and management. In contrast to universal compressors, RDF compression techniques are able to detect and exploit specific forms of redundancy in RDF data. Thus, state-of-the-art RDF compressors excel at exploiting syntactic and semantic redundancies, i.e., repetitions in the serialization format and information that can be inferred implicitly. However, little attention has been paid to the existence of structural patterns within the RDF dataset; i.e. structural redundancy. In this paper, we analyze structural regularities in real-world datasets, and show three schema-based sources of redundancies that underpin the schema-relaxed nature of RDF. Then, we propose RDF-Tr (RDF Triples Reorganizer), a preprocessing technique that discovers and removes this kind of redundancy before the RDF dataset is effectively compressed. In particular, RDF-Tr groups subjects that are described by the same predicates, and locally re-codes the objects related to these predicates. Finally, we integrate RDF-Tr with two RDF compressors, HDT and k2-triples. Our experiments show that using RDF-Tr with these compressors improves by up to 2.3 times their original effectiveness, outperforming the most prominent state-of-the-art techniques

Switching TNF antagonists in patients with chronic arthritis: An observational study of 488 patients over a four-year period

The objective of this work is to analyze the survival of infliximab, etanercept and adalimumab in patients who have switched among tumor necrosis factor (TNF) antagonists for the treatment of chronic arthritis. BIOBADASER is a national registry of patients with different forms of chronic arthritis who are treated with biologics. Using this registry, we have analyzed patient switching of TNF antagonists. The cumulative discontinuation rate was calculated using the actuarial method. The log-rank test was used to compare survival curves, and Cox regression models were used to assess independent factors associated with discontinuing medication. Between February 2000 and September 2004, 4,706 patients were registered in BIOBADASER, of whom 68% had rheumatoid arthritis, 11% ankylosing spondylitis, 10% psoriatic arthritis, and 11% other forms of chronic arthritis. One- and two-year drug survival rates of the TNF antagonist were 0.83 and 0.75, respectively. There were 488 patients treated with more than one TNF antagonist. In this situation, survival of the second TNF antagonist decreased to 0.68 and 0.60 at 1 and 2 years, respectively. Survival was better in patients replacing the first TNF antagonist because of adverse events (hazard ratio (HR) for discontinuation 0.55 (95% confidence interval (CI), 0.34-0.84)), and worse in patients older than 60 years (HR 1.10 (95% CI 0.97-2.49)) or who were treated with infliximab (HR 3.22 (95% CI 2.13-4.87)). In summary, in patients who require continuous therapy and have failed to respond to a TNF antagonist, replacement with a different TNF antagonist may be of use under certain situations. This issue will deserve continuous reassessment with the arrival of new medications. © 2006 Gomez-Reino and Loreto Carmona; licensee BioMed Central Ltd